CCNE1 and breast carcinoma: Cyclin E, an activator of CDK2, when ectopically over-expressed is able to abrogate the anti-proliferative actions of tamoxifen on breast cancer cells [9] and is also shown to be a good indicator for endocrine-therapy failure [43,44].